Curated News
By: NewsRamp Editorial Staff
November 05, 2026
Annovis Bio Prices $21M Offering to Advance Buntanetap Trials
TLDR
- Annovis Bio raised $21 million at $1 per share to fund Phase 3 buntanetap trials, gaining a cash runway advantage in the Alzheimer's and Parkinson's race.
- Annovis Bio priced 21 million shares and warrants at $1 each, with Canaccord as bookrunner, to fund buntanetap development through a five-year warrant structure.
- Annovis Bio's $21 million offering accelerates buntanetap trials, aiming to halt neurodegeneration and improve cognitive and motor function for Alzheimer's and Parkinson's patients.
- Annovis Bio's buntanetap is an oral drug that targets RNA to block multiple neurotoxic proteins, including amyloid beta, tau, and alpha-synuclein, in one daily pill.
Impact - Why it Matters
This financing provides Annovis Bio with approximately $21 million in gross proceeds to advance buntanetap, its investigational oral therapy for Alzheimer’s and Parkinson’s diseases, through Phase 3 clinical development. For patients and families affected by these neurodegenerative conditions, which currently have limited disease-modifying treatments, the progress of buntanetap represents a potential new approach that targets multiple neurotoxic proteins involved in neurodegeneration. The offering also signals continued investor support for Annovis’s pipeline, which is crucial for sustaining long-term research and development in a challenging biotech funding environment. If buntanetap succeeds in clinical trials, it could meaningfully alter the treatment landscape for Alzheimer’s and Parkinson’s, diseases that affect millions worldwide and impose a substantial burden on caregivers and healthcare systems.
Summary
Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, has announced the pricing of an underwritten public offering of 19 million common shares, pre-funded warrants to purchase up to 2 million shares, and accompanying warrants to purchase up to 21 million shares. The combined offering price is $1 per common share and accompanying warrant, or $0.9999 per pre-funded warrant and accompanying warrant. The warrants have an exercise price of $1 per share and expire five years after issuance. Annovis expects gross proceeds of approximately $21 million, before deducting offering expenses and excluding any potential proceeds from warrant exercises. The offering is expected to close on or about Nov. 6, 2026, subject to customary closing conditions. Canaccord Genuity is acting as sole bookrunner for the offering.
The net proceeds will primarily support continued clinical development of Annovis’s investigational oral therapy buntanetap for Alzheimer’s disease and Parkinson’s disease, as well as working capital and general corporate purposes. Buntanetap (formerly posiphen) is a once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins—including APP and amyloid beta, tau, alpha-synuclein, and TDP-43—through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X. The full press release is available at https://ibn.fm/DGBQK, and the latest news and updates relating to ANVS can be found in the company’s newsroom at https://ibn.fm/ANVS.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company’s lead drug candidate, buntanetap, represents a novel approach to neurodegeneration by targeting multiple neurotoxic proteins simultaneously. This financing bolsters Annovis’s balance sheet as it advances its Phase 3 clinical program, a critical stage for any biotech company. The offering, managed by Canaccord Genuity, reflects investor interest in the company’s pipeline and provides the capital needed to continue developing buntanetap, which, if successful, could offer a new therapeutic option for patients with Alzheimer’s and Parkinson’s diseases.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Annovis Bio Prices $21M Offering to Advance Buntanetap Trials
